NASDAQ:OPGN
OpGen, Inc. Stock News
$0.535
+0.0201 (+3.90%)
At Close: Apr 29, 2024
OpGen's Earnings Outlook
10:04am, Wednesday, 24'th Mar 2021
OpGen (NASDAQ:OPGN) unveils its next round of earnings this Thursday, March 25. Get prepared with Benzinga's ultimate preview for OpGen's Q4 earnings.
OpGen, Inc. (OPGN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
01:16pm, Thursday, 18'th Mar 2021
OpGen, Inc. (OPGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
OPGN Stock Price Increases Over 40% Pre-Market: Why It Happened
04:58am, Tuesday, 09'th Mar 2021
The stock price of OpGen Inc (NASDAQ: OPGN) is trading at over 40% pre-market. This is why it happened.
Why Immunovant, Anchiano, OpGen Are Rallying Today
01:09pm, Monday, 08'th Mar 2021
Immunovant, Inc. (NASDAQ: IMVT), Anchiano Therapeutics Ltd. (NASDAQ: ANCN) and OpGen, Inc. (NASDAQ: OPGN) are among the biggest healthcare gainers on Monday.
OPGN Stock: 9 Things for OpGen Investors to Know as Shares Skyrocket
11:59am, Monday, 08'th Mar 2021
OpGen (OPGN) stock is flying high on Monday following results from a study published in a peer-reviewed publication concerning coronavirus. The post OPGN Stock: 9 Things for OpGen Investors to Know as
OPGN Stock Price Increases Over 10% Pre-Market: Why It Happened
08:30am, Monday, 08'th Mar 2021
The stock price of OpGen Inc (NASDAQ: OPGN) has increased by over 10% pre-market. This is why it happened.
Karolinska Institutet Study highlights Unyvero HPN demonstrating a higher diagnostic yield than bacterial culture, enabling rapid diagnosis of pathogens of concern in these patients
OPGN Stock Price Increases Over 12% Pre-Market: Why It Happened
08:42am, Monday, 01'st Mar 2021
The stock price of OpGen Inc (NASDAQ: OPGN) has increased by over 12% pre-market. This is why it happened.
OpGen Wins Chinese NMPA Approval for the Curetis Unyvero System
07:30am, Monday, 01'st Mar 2021
GAITHERSBURG, Md., March 01, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help com
Study highlights best practice techniques for accurate antimicrobial resistance prediction from whole-genome sequencing data
OpGen Announces Preliminary Unaudited Revenue for Fiscal 2020 and Provides Business Update
07:30am, Wednesday, 13'th Jan 2021
GAITHERSBURG, Md., Jan. 13, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help comb
OpGen Subsidiary Curetis and Annar Enter into Unyvero Distribution Partnership for Colombia
07:30am, Tuesday, 05'th Jan 2021
GAITHERSBURG, Md. and HOLZGERLINGEN, Germany, Jan. 05, 2021 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and
OpGen Announces Planned Leadership Transition at Next Generation Sequencing and Bioinformatics Subsidiary Ares Genetics
07:30am, Wednesday, 09'th Dec 2020
Dr. Arne Materna to join Ares Genetics as new Managing Director and CEO to lead Ares into next phase of its growth
Extended collaboration with leading global generics company Sandoz for optimal antibiotic drug positioning by predictive antibiotic susceptibility testing
OpGen Reports Third Quarter 2020 Financial Results and Provides Business Update
04:05pm, Wednesday, 11'th Nov 2020
Conference call to be held at 4:30 p.m. Eastern Time today
